Design, Synthesis, Docking Study and Anticancer Evaluation of New Trimethoxyphenyl Pyridine Derivatives As Tubulin Inhibitors and Apoptosis Inducers

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 2

PMID 35494162

Authors

Mohamed Hagras

Asmaa A Mandour

Esraa A Mohamed

Eslam B Elkaeed

Ibrahim M M Gobaara

Ahmed B M Mehany

Nasser S M Ismail

Hanan M Refaat

Affiliations

Soon will be listed here.

Abstract

Microtubules have become an appealing target for anticancer drug development including mainly colchicine binding site inhibitors (CBSIs). A new series of novel trimethoxypyridine derivatives were designed and synthesized as tubulin targeting agents. anti-proliferative activities of the tested compounds compared to colchicine against hepatocellular carcinoma (HepG-2), colorectal carcinoma (HCT-116), and breast cancer (MCF-7) was carried out. Most of compounds showed significant cytotoxic activities. Compounds Vb, Vc, Vf, Vj and VI showed superior anti-proliferative activities to colchicine. Where compound VI showed IC values of 4.83, 3.25 and 6.11 μM compared to colchicine (7.40, 9.32, 10.41 μM) against HCT 116, HepG-2 and MCF-7, respectively. The enzymatic activity against tubulin enzyme was carried out for the compounds that showed high anti-proliferative activity. Also, compound VI exhibited the highest tubulin polymerization inhibitory effect with an IC value of 8.92 nM compared to colchicine (IC value = 9.85 nM). Compounds Vb, Vc, Vf, Vj, & VIIIb showed promising activities with IC values of 22.41, 17.64, 20.39, 10.75, 31.86 nM, respectively. Cell cycle and apoptosis test for compound VI against HepG-2 cells, indicated that compound VI can arrest cell cycle at G2/M phase, and can cause apoptosis at pre-G1 phase, with high apoptotic effect 18.53%. Molecular docking studies of the designed compounds confirmed the essential hydrogen bonding with CYS241 beside the hydrophobic interaction at the binding site compared to reference compounds which assisted in the prediction of the structure requirements for the detected antitumor activity.

Citing Articles

2-Chloro-3-cyano-4-nitrobenzyl pyridinium bromide as a potent anti-lung cancer molecule prepared using a single-step solvent-free method.

Govindaraj S, Ganesan K, Elumalai P, Jeevitha R, Subramani A, Amanullah M RSC Adv. 2024; 14(34):24898-24909.

PMID: 39119280 PMC: 11309018. DOI: 10.1039/d4ra03538k.

References

Thabrew M, Hughes R, McFarlane I . Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol. 1997; 49(11):1132-5. DOI: 10.1111/j.2042-7158.1997.tb06055.x. View

Dong M, Liu F, Zhou H, Zhai S, Yan B . Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site. Molecules. 2016; 21(10). PMC: 6273505. DOI: 10.3390/molecules21101375. View

Guggilapu S, Guntuku L, Reddy T, Nagarsenkar A, Sigalapalli D, Naidu V . Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors. Eur J Med Chem. 2017; 138:83-95. DOI: 10.1016/j.ejmech.2017.06.025. View

Patterson D, Rustin G . Vascular damaging agents. Clin Oncol (R Coll Radiol). 2007; 19(6):443-56. DOI: 10.1016/j.clon.2007.03.014. View

Wang J, Lenardo M . Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci. 2000; 113 ( Pt 5):753-7. DOI: 10.1242/jcs.113.5.753. View

Al-Warhi T, Abo-Ashour M, Almahli H, Alotaibi O, Al-Sanea M, Al-Ansary G . Novel [(-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and studies. J Enzyme Inhib Med Chem. 2020; 35(1):1300-1309. PMC: 7717600. DOI: 10.1080/14756366.2020.1773814. View

Dumontet C, Jordan M . Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010; 9(10):790-803. PMC: 3194401. DOI: 10.1038/nrd3253. View

Pettit G, TEMPLE Jr C, Narayanan V, Varma R, Simpson M, Boyd M . Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 1995; 10(4):299-309. View

Eldehna W, Hassan G, Al-Rashood S, Al-Warhi T, Altyar A, Alkahtani H . Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem. 2019; 34(1):322-332. PMC: 6366416. DOI: 10.1080/14756366.2018.1547286. View

10.

Ravelli R, Gigant B, Curmi P, Jourdain I, Lachkar S, Sobel A . Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004; 428(6979):198-202. DOI: 10.1038/nature02393. View

11.

Xu F, Li W, Shuai W, Yang L, Bi Y, Ma C . Design, synthesis and biological evaluation of pyridine-chalcone derivatives as novel microtubule-destabilizing agents. Eur J Med Chem. 2019; 173:1-14. DOI: 10.1016/j.ejmech.2019.04.008. View

12.

Denizot F, Lang R . Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986; 89(2):271-7. DOI: 10.1016/0022-1759(86)90368-6. View

13.

Abd El-Sattar N, Badawy E, AbdEl-Hady W, Abo-Alkasem M, Mandour A, Ismail N . Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity. Chem Pharm Bull (Tokyo). 2021; 69(1):106-117. DOI: 10.1248/cpb.c20-00714. View

14.

Yue Q, Liu X, Guo D . Microtubule-binding natural products for cancer therapy. Planta Med. 2010; 76(11):1037-43. DOI: 10.1055/s-0030-1250073. View

15.

Kumar B, Kumar A, Singh J, Hasanain M, Singh A, Fatima K . Synthesis of 2-alkoxy and 2-benzyloxy analogues of estradiol as anti-breast cancer agents through microtubule stabilization. Eur J Med Chem. 2014; 86:740-51. DOI: 10.1016/j.ejmech.2014.09.033. View

16.

Jordan M, Kamath K . How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 2008; 7(8):730-42. DOI: 10.2174/156800907783220417. View

17.

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

18.

Checchi P, Nettles J, Zhou J, Snyder J, Joshi H . Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci. 2003; 24(7):361-5. DOI: 10.1016/S0165-6147(03)00161-5. View

19.

Prota A, Danel F, Bachmann F, Bargsten K, Buey R, Pohlmann J . The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol. 2014; 426(8):1848-60. DOI: 10.1016/j.jmb.2014.02.005. View

20.

Lu Y, Chen J, Xiao M, Li W, Miller D . An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012; 29(11):2943-71. PMC: 3667160. DOI: 10.1007/s11095-012-0828-z. View